Why the study?
Does doxorubicin produce tumor regression in children with malignant solid tumors?
Does doxorubicin produce tumor regression in children with malignant solid tumors?
Doxorubicin administered at 50 mg/sq m at two-week intervals is effective for tumor regression in pediatric solid tumors while allowing adequate time for toxicity evaluation.
Answers are grounded in this paper and cite their sources.
Early signal of activity in pediatric tumors; leaves open confirmation of benefit, dosing, and safety in controlled trials.
Doxorubicin (adriamycin) was administered to 35 children with malignant solid tumors to further evaluate its usefulness and toxicity. Two dosage schedules were used: 25 mg/sq m of body surface area weekly, and 25 mg/sq m on two consecutive days and then every two weeks. The agent produced tumor regression in 17 children; the tumors included osteosarcoma, neuroblastoma, Wilms tumor, reticulum cell (histiocytic) lymphoma, and hepatoblastoma. Toxic reactions including alopecia, hematopoietic depression, vomiting, mucosal ulcerations, and weight loss were similar with each schedule. Administration of doxorubicin in a dosage of 50 mg/sq m at two-week intervals allows time for detection of toxic reactions and evaluation of tumor response before administration of subsequent doses.
No takes yet. Share an insight, caveat, or question.
Charles B. Pratt (1974) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: